Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma (PROVe)
A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®
Sponsor: Helsinn Therapeutics (U.S.), Inc
This observational or N/A phase trial investigates Mycosis Fungoides and is currently completed. Helsinn Therapeutics (U.S.), Inc leads this study, which shows 15 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 10 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
Apr 2020 — Jan 2021 [monthly]
Completed
-
Jan 2020 — Apr 2020 [monthly]
Completed
-
Oct 2019 — Jan 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jan 2019 — Oct 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jan 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Helsinn Therapeutics (U.S.), Inc
For direct contact, visit the study record on ClinicalTrials.gov .